California based Viveve Medical Inc. priced its previously announced public offering of 10 million shares at $3 apiece.
The offering is expected to close by Feb. 12 with Cowen acting as sole book-running manager and Raymond James acting as lead manager. Ladenburg Thalmann & Co. Inc. and Maxim Group LLC are acting as co-managers for the offering.
The underwriters can purchase up to an additional 1.5 million shares of the company.
The women's health company plans to use the net proceeds to fund the commercialization of its products, clinical research and development, working capital, and general corporate purposes.
